Raymond James & Associates Boosts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Raymond James & Associates raised its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 4.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,279 shares of the biopharmaceutical company’s stock after buying an additional 2,045 shares during the period. Raymond James & Associates’ holdings in Catalyst Pharmaceuticals were worth $845,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. SG Americas Securities LLC bought a new position in Catalyst Pharmaceuticals in the 3rd quarter valued at $502,000. Exchange Traded Concepts LLC bought a new position in shares of Catalyst Pharmaceuticals in the third quarter worth about $365,000. Handelsbanken Fonder AB increased its stake in Catalyst Pharmaceuticals by 92.3% in the 3rd quarter. Handelsbanken Fonder AB now owns 27,877 shares of the biopharmaceutical company’s stock worth $326,000 after buying an additional 13,377 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Catalyst Pharmaceuticals by 25.7% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,692 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 5,044 shares in the last quarter. Finally, Assetmark Inc. boosted its position in Catalyst Pharmaceuticals by 11.1% in the 3rd quarter. Assetmark Inc. now owns 62,173 shares of the biopharmaceutical company’s stock valued at $727,000 after buying an additional 6,218 shares during the period. Institutional investors own 79.22% of the company’s stock.

Analyst Ratings Changes

CPRX has been the topic of several research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $34.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, March 22nd. StockNews.com upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 21st. Bank of America initiated coverage on Catalyst Pharmaceuticals in a report on Thursday, March 7th. They issued a “buy” rating and a $23.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $24.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, March 1st. Finally, TheStreet raised shares of Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Tuesday, March 12th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $26.43.

Insider Activity

In other news, Director David S. Tierney sold 25,000 shares of the business’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $15.68, for a total transaction of $392,000.00. Following the completion of the transaction, the director now directly owns 348,874 shares of the company’s stock, valued at $5,470,344.32. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 12.10% of the company’s stock.

Catalyst Pharmaceuticals Trading Down 0.2 %

Shares of CPRX stock opened at $15.10 on Tuesday. Catalyst Pharmaceuticals, Inc. has a twelve month low of $11.09 and a twelve month high of $17.76. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of 24.75, a PEG ratio of 0.83 and a beta of 0.89. The company’s 50-day moving average price is $15.44 and its 200-day moving average price is $14.59.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.04. The company had revenue of $110.57 million for the quarter, compared to analysts’ expectations of $105.78 million. Catalyst Pharmaceuticals had a net margin of 17.93% and a return on equity of 26.56%. As a group, equities research analysts predict that Catalyst Pharmaceuticals, Inc. will post 1.81 EPS for the current year.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.